Treatment of Macular Edema After Cataract Surgery With Subconjunctival Aflibercept — ACME  

Irvine-Gass Syndrome Clinical Trial

Official title: Subconjunctival Aflibercept Injection for Pseudophakic Cystoid Macular Edema

Status Terminated

Clinical Trial Summary

This research study is being conducted to determine the safety and tolerability of subconjunctival injections of aflibercept in the treatment of pseudophakic cystoid macular edema that has not responded well to first-line standard of care treatment (eye drops).

Pseudophakic cystoid macular edema (CME) is swelling of the retina that can occur weeks or years after cataract surgery and typically results in decreased vision. Subconjunctival injections are injections placed just beneath the clear membrane (conjunctiva) of the eye.

A recent report of one patient who received two subconjunctival injections of a similar medication to the one being studied here indicated that subconjunctival injections of this class of medication may be an effective and less invasive alternative to intravitreal injections for pseudophakic CME. Because of the similarity of the drugs and the patient's treatment success, we would like to see if subconjunctival injection(s) of aflibercept will work in treating pseudophakic CME. If successful, the risk of an intraocular infection and glaucoma that comes with standard of care treatments might be greatly reduced.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Irvine-Gass Syndrome
• Macular Edema

• NCT number: NCT03396861
• Study type: Interventional
• Source: Tufts Medical Center
• Status: Terminated
• Phase: Phase 1
• Start date: February 22, 2019
• Completion date: January 2, 2020